FTH Stock — Faeth Therapeutics, Inc.

Faeth Therapeutics, Inc. (FTH)

Updated October 16, 2026.

FTH is a Stock. Total return is -95.0% over the past 5.7 years, 208.4 points behind SPY at 113.4%.

Faeth Therapeutics is a clinical-stage biotechnology company developing cancer therapeutics, including PIKTOR for endometrial and breast cancer, Solnerstotug targeting the immune checkpoint VISTA, and several monoclonal antibody candidates in early development. The company does not currently distribute dividends. This stock may appeal to investors with risk tolerance for early-stage biotech development and no need for current income.

FTH performance versus SPY

Price and return data through 2026-10-16.

Total return is -95.0% over the past 5.7 years, 208.4 points behind SPY at 113.4%. Over the past year its total return — price change plus distributions reinvested — is 7.0%. Its deepest 1-year drawdown was 69.2%.

FTH key facts

Asset type

Stock

Asset class

Equity

Inception date

02/04/2021

Distribution frequency

None

Last close

$18.80 (as of 2026-10-16)

Market cap

$485,799,990

Average volume

595930.0

Beta

-0.287

Payout ratio

0.0%

EPS

$-68.41

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

FTH risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 69.2%.

Who may consider FTH — and who may not

It is a weaker fit for investors who need monthly cash flow (FTH does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on FTH

• All tickers starting with F

Tagged: Healthcare.

Frequently asked questions